Cover Image

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we present an unprecedented integrated summary of the immunogenicity of CYD-TDV to identify the parameters driving the neutralizing...

Full description

Saved in:

Bibliographic Details
Main Authors:	Claire Vigne (Author), Martin Dupuy (Author), Aline Richetin (Author), Bruno Guy (Author), Nicholas Jackson (Author), Matthew Bonaparte (Author), Branda Hu (Author), Melanie Saville (Author), Danaya Chansinghakul (Author), Fernando Noriega (Author), Eric Plennevaux (Author)
Format:	Book
Published:	Taylor & Francis Group, 2017-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A recombinant live attenuated tetravalent vaccine for the prevention of dengue
by: Bruno Guy, et al.
Published: (2017)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
by: Shibadas Biswal, et al.
Published: (2021)

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
by: Ngoc Huu Tran, et al.
Published: (2019)

The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017)

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
by: Sophia Gailhardou, et al.
Published: (2016)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
by: Stephen S Whitehead, et al.
Published: (2017)

Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
by: Anke Harenberg, et al.
Published: (2016)

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
by: Claire Y-H Huang, et al.
Published: (2013)

Efficacy of tetravalent dengue vaccine: A systematic review and meta-analysis
by: Ashish Wasudeo Khobragade, et al.
Published: (2021)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
by: Philip K Russell, et al.
Published: (2016)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020)

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults
by: Susan B. Manoff, et al.
Published: (2019)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
by: Vianney Tricou, et al.
Published: (2023)

Development and evaluation of a tetravalent botulinum vaccine
by: Dan-Yang Shi, et al.
Published: (2022)

A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil
by: José Cássio de Moraes, et al.
Published: (2022)

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
by: Juliana Park, et al.
Published: (2021)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
by: Laura J White, et al.
Published: (2021)

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
by: Fiona R Strouts, et al.
Published: (2016)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
by: Philippe Moris, et al.
Published: (2019)

Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
by: Scott B. Halstead
Published: (2018)

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
by: Sanford R Kimmel
Published: (2008)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
by: Sanjay S. Patel, et al.
Published: (2023)

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules
by: Eduardo Lazcano-Ponce, et al.
Published: (2018)

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.
by: Philippe J Guerin, et al.
Published: (2008)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
by: Stefan W Metz, et al.
Published: (2018)

A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants
by: Lalitendu Mohanty, et al.
Published: (2017)

Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines
by: Paolo Bonanni, et al.
Published: (2020)

Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa
by: Anthonet Koen, et al.
Published: (2021)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial
by: Shrikant Sharma, et al.
Published: (2018)

An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
by: Chung-Tao Tang, et al.
Published: (2015)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial
by: Sumantra Sarkar, et al.
Published: (2021)

Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells.
by: Taweewun Hunsawong, et al.
Published: (2015)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
by: Juan Li, et al.
Published: (2021)

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
by: Eva Hong, et al.
Published: (2017)

Factors influencing the immunogenicity of influenza vaccines
by: Simin Wen, et al.
Published: (2021)

Methods for predicting vaccine immunogenicity and reactogenicity
by: Patrícia Gonzalez-Dias, et al.
Published: (2020)

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series
by: Juliana Park, et al.
Published: (2020)

Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults
by: Osamu Matsuoka, et al.
Published: (2018)

Long time immunogenicity of measles vaccine in the vaccination era: An open question
by: Maria Serena Gallone, et al.
Published: (2017)

Immunogenicity and Complications of the Pentavalent Vaccine in Iranian Children
by: Mina Ekrami Noghabi, et al.
Published: (2021)